China's NMPA grants Class III registration to Neuracle NEO, first invasive BCI approved for commercial clinical use

Neuracle/NEO Implantable Brain-Computer Interface

China's National Medical Products Administration (NMPA) granted Class III registration to Neuracle Technology's NEO system, an implantable brain-computer interface for patients with C2-C6 cervical spinal cord injuries aged 18-60 with retained upper arm function. This made NEO the first invasive BCI cleared for commercial prescription anywhere in the world.